ORBIMED CAPITAL LLC
CIK 1157524 · last filed 2026-04-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALEC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
54TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRLD | Director | 1,126,126 | $3.70 | $4.17M | $65.00M | 3 | 2026-04-23 |
| SPRY | Director | 269,323 | $3.92 | $1.06M | -$3.26M | 1 | 2024-08-28 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 1,368,339 | $2.65 | $3.63M | $36.56M | 3 | 2023-05-08 |
| ARQT | Director | 3,534,537 | $31.81 | $112.43M | $43.84M | 3 | 2022-06-28 |
| PMVP | 10%+ Owner | 109,500 | $1.13 | $123.7K | -$41.06M | 1 | 2022-03-31 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 3,221,637 | $2.65 | $8.54M | -$1.85M | 1 | 2021-08-30 |
| ALEC | Director | 2,650,781 | $1.83 | $4.85M | -$60.17M | 3 | 2019-12-26 |
Recent Filings · Page 2 of 4
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-10-02 | DMRA | Notice (144) | −57,312 | -$41.3K | EDGAR |
| 2023-08-30 | DMRA | Notice (144) | −119,679 | -$69.4K | EDGAR |
| 2023-08-21 | DMRA | Notice (144) | −147,910 | -$91.3K | EDGAR |
| 2023-08-15 | DMRA | Notice (144) | −114,843 | -$86.1K | EDGAR |
| 2023-07-31 | DMRA | Notice (144) | −246,830 | -$745.4K | EDGAR |
| 2023-07-25 | DMRA | Notice (144) | −8,100 | -$19.0K | EDGAR |
| 2023-07-13 | DMRA | Notice (144) | −14,700 | -$37.5K | EDGAR |
| 2023-06-15 | — | Notice (144) | −116,000 | -$664.7K | EDGAR |
| 2023-06-15 | — | Notice (144) | −205,000 | -$1.17M | EDGAR |
| 2023-06-12 | KROS | Notice (144) | −170,000 | -$7.46M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.